Immune checkpoint: The novel target for antitumor therapy

• Published in: Genes & diseases Vol. 8; no. 1; pp. 25 - 37
• Main Authors: Jiang, Xianghu, Liu, Guohong, Li, Yirong, Pan, Yunbao
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.01.2021; Chongqing Medical University; KeAi Communications Co., Ltd
• Subjects: Circulating tumor DNA (ctDNA); Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); Exosome; Immune checkpoint; Lymphocyte-activation gene 3 (LAG-3); Programmed cell death protein ligand 1 (PD-L1); Programmed death-1 receptor (PD-1); Review; T cell immunoglobulin domain and mucin domain 3 (TIM-3); T cell immunoglobulin domain and mucin domain 3 (TIM-3); Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); Circulating tumor DNA (ctDNA); Immune checkpoint; Exosome; Programmed cell death protein ligand 1 (PD-L1); Lymphocyte-activation gene 3 (LAG-3); Programmed death-1 receptor (PD-1)

Inhibitory checkpoint molecules include programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1), cytotoxic T lymphocyte antigen-4 (CTLA-4), human endogenous retrovirus-H Long terminal repeat-associating 2 (HHLA2), B7 homolog 4 protein (B7-H4), T cell membrane protein-3 (TIM-3) and Lym...